Skip to content
Screener

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$1.48B+44.6%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$3.64M-99.2%
Vera Therapeutics logo
Vera TherapeuticsVERA
$3.94M+157%
PVL
Palvella TherapeuticsPVLA
$214.73M+17,964%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from the exercise of warrants1,618
Proceeds from issuance of common stock upon exercises of stock options6,9343,060
Proceeds from issuance of common stock under employee stock purchase plan1,270561
Net cash provided by financing activities331,4789,976
Net increase (decrease) in cash and cash equivalents(47,396)17,730
Cash and cash equivalents at beginning of period212,38299,594
Cash and cash equivalents at end of period$164,986$117,324
Supplemental disclosure of cash flow information

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s financing cash flow?
Viridian Therapeutics, Inc. (VRDN) reported financing cash flow of $325.12M in Q2 2026.
How has Viridian Therapeutics, Inc.'s financing cash flow changed year-over-year?
Viridian Therapeutics, Inc.'s financing cash flow increased by 42455.1% year-over-year, from $764K to $325.12M.
What is the long-term trend for Viridian Therapeutics, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s financing cash flow has grown at a 35.9% compound annual growth rate (CAGR), from $125.28M to $426.74M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Viridian Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude